Enzo Biochem (ENZB) AI Stock Analysis

• Market Cap: $35.81M
• Dividend Yield: N/A
• Average Volume (3M): 669.40K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.78
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 125
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.05
• Shares Outstanding: 52,432,130
• 10 Day Avg. Volume: 1,898,960
• 30 Day Avg. Volume: 669,401
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 60 Neutral
• Price Target: $0.50 ▼(-26.47%Downside)

The primary positive driver for Enzo Biochem's stock score is the announced merger with Battery Ventures, offering a substantial premium. However, significant financial and valuation challenges persist, including declining revenues and negative margins. While technical analysis shows bullish momentum, overbought signals warrant caution.

Enzo Biochem Business Overview & Revenue Model

Company Description

Enzo Biochem, Inc. (ENZB) is a life sciences and biotechnology company specializing in the development, manufacture, and sale of innovative products and technologies for research, diagnostics, and therapeutics. The company operates primarily through two segments: Enzo Clinical Labs and Enzo Life Sciences. Enzo Clinical Labs provides a full range of clinical laboratory and pathology services, while Enzo Life Sciences develops, manufactures, and markets reagents, assays, and systems used in medical research and drug development.

How the Company Makes Money

Enzo Biochem generates revenue primarily through its two operating segments. Enzo Clinical Labs earns money by providing diagnostic and clinical laboratory testing services to physicians, medical centers, and other healthcare providers. This includes routine blood tests, molecular diagnostics, and specialized testing services. Enzo Life Sciences generates revenue by selling a wide range of life sciences products, including reagents, assays, and kits to academic institutions, biopharmaceutical companies, and laboratories worldwide. The company also benefits from partnerships and licensing agreements that leverage its proprietary technologies and intellectual property, contributing to its earnings.

Enzo Biochem Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Enzo Biochem Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.68
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENZB, the sentiment is Positive. The current price of 0.68 is above the 20-day moving average (MA) of 0.61, above the 50-day MA of 0.57, and below the 200-day MA of 0.70, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 68.22 is Neutral, neither overbought nor oversold. The STOCH value of 98.04 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ENZB.

Enzo Biochem Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ENZB	60 Neutral	$35.81M	―	-13.95%	―	―	―
TVRD	57 Neutral	$200.79M	―	-414.88%	―	-65.96%	40.80%
IGC	54 Neutral	$25.75M	―	-104.33%	―	-5.50%	56.57%
Sector *	51 Neutral	$7.50B	0.32	-61.87%	2.27%	17.10%	1.59%
ENLV	36 Underperform	$28.14M	―	-60.35%	―	―	53.95%
BCAB	35 Underperform	$23.23M	―	-246.21%	―	―	44.38%
NRSN	30 Underperform	$45.58M	―	-2880.11%	―	―	31.09%

Enzo Biochem Corporate Events

Enzo Biochem Announces Merger with Battery Ventures

On June 23, 2025, Enzo Biochem, Inc. entered into a merger agreement to be acquired by Battery Ventures for $0.70 per share in cash, totaling approximately $37 million. This transaction, which follows a strategic review by Enzo’s Board, represents a 75% premium to the company’s closing price on April 22, 2025. The merger is subject to customary closing conditions, including shareholder approval, and is expected to close in the third quarter of 2025. Upon completion, Enzo will become a privately held company, and its shares will no longer be publicly traded. The acquisition is seen as a strategic move to maximize shareholder value.